Requests for proposals

Working closely with Kebbi state government officials and health facilities, PATH will deploy mobile immunization teams (MITs) to 16 Local Government Areas (LGAs) in Kebbi, focusing on settlements and villages more than 5 km from a fixed vaccination post and other hard-to-reach populations. We will work with local officials to develop microplans to identify the missed children, and the MITs will use the microplans to reach them. The MITs will host vaccination sessions in central community locations and will record vaccinations for inclusion in the fixed post’s record-keeping. The project will include a robust monitoring and evaluation scope to track outcomes for the intended population (increased access, uptake, and trust) and for the immunization system (improved planning and delivery capacity, quality data collection, recording, and data use).

Find a detailed scope of work and requirements, risk assessment, and budget instructions at these links.

Despite high rates of vaccination with acellular pertussis (aP) vaccines, the incidence of Bordetella pertussis infections is on the rise in the United States and other high-income countries. 

Because the first routine pertussis vaccination occurs at 6–8 weeks of age, infants less than 2 months of age have the highest rate of serious clinical complications requiring hospitalization and the highest mortality rate following pertussis exposure.

PATH is seeking a qualified testing facility to determine the required dose of anti-pertussis toxoid serum generated in adult baboons to achieve a titer of 5 international units (IU) when administered to eight-week-old baboons.

Find detailed scope of work and requirements here.